Cardio-vascular
Refine Search
Pharmaceutical
Amarin has announced primary results from a trial of Vascepa (icosapent ethyl) which show a 25% relative risk reduction (RRR), including 20% reduction in cardiovascular death. 12 November 2018
Biotechnology
Shares in Anglo-Swedish pharma major AstraZeneca were nearly 7% higher than they were a week ago on Monday lunchtime as data on Farxiga (dapagliflozin) bumped up the company’s stock further. 12 November 2018
Pharmaceutical
Sanofi has presented a new analysis on mortality from the ODYSSEY OUTCOMES trial at the annual meeting of the American Heart Association. 12 November 2018
Pharmaceutical
At the annual meeting of the American Heart Association, new real-world data around Eliquis (apixaban) have been presented by the New York-based firms Bristol-Myers Squibb and Pfizer. 12 November 2018
Pharmaceutical
AstraZeneca’s enormous investment in R&D in the last five years means that pipeline updates are seen as more important than quarterly results – a fact that was again evident on Thursday. 8 November 2018
Pharmaceutical
Proving that diabetes drugs can reduce cardiovascular (CV) events is seen as vital by drugmakers in the space, and US pharma major Eli Lilly has responded to progress made by other treatments in this area by presenting data on Trulicity (dulaglutide). 6 November 2018
Pharmaceutical
Boehringer Ingelheim and Eli Lilly have released positive initial results from the real-world EMPRISE study examining cardiovascular outcomes related to Jardiance (empagliflozin). 5 November 2018
Biotechnology
Eli Lilly has splashed out on a licensing and research collaboration in RNA interference (RNAi). 29 October 2018
Biotechnology
Two major new listings on the Australian Pharmaceutical Benefits Scheme (PBS) have the potential to extend the lives of Australians with advanced lung cancer and those at risk of a heart attack, saving patients up to nearly A$190,000 ($135,714) a year. 29 October 2018
Pharmaceutical
Featured regulatory news last week included US Food and Drug Administration approval for Sanofi and Regeneron’s Dupixent in the all important asthma indication. Among new clinical trial data, there was disappointment for Merrimack Pharma’s MM-121 in a lung cancer study, and Eisai and Biogen presented new data on their Alzheimer’s candidate BAN2401, but failed to win over doubters. On the deal-making front, AstraZeneca’s decision to expand its collaboration with France’s Innate Pharma in immuno-oncology with candidate monalizumab suggests a turnaround in the latter’s fortunes. Finally, Amgen announced a massive 60% cut in the list price of its cholesterol drug Repatha. 28 October 2018
Biotechnology
Amgen said yesterday that it is making its PCSK-9 inhibitor Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price. 25 October 2018
Pharmaceutical
Shares in US pharma major Bristol-Myers Squibb were down by 3% in the opening half hour of trading on Thursday after the company announced a mixed set of financial results for the third quarter of 2018. 25 October 2018
Biotechnology
The UK Secretary of State for Health and Social Care has announced that the PCSK9 inhibitor class has been selected as a treatment that needs to see a rapid increase in uptake to ensure that patients, and the National Health Service (NHS), get the benefits of this class of medicines. 24 October 2018
Pharmaceutical
Shanghai-listed Zhejiang Huahai Pharmaceutical has been placed under close supervision by European authorities, after an inspection uncovered “quality management weaknesses” at the company’s Chuannan site in Linhai, China. 16 October 2018
Pharmaceutical
Eisai has presented data showing the potential of its anti-obesity drug Belviq (lorcaserin hydrochloride) to prevent and cause remission of type 2 diabetes. 5 October 2018
Biotechnology
AstraZeneca last week unveiled a three-year investment plan in Taiwan. 2 October 2018
Pharmaceutical
Last week’s top news stories including some positive and exciting new research data, including Amarin's trial of Vascepa in cardiovascular outcomes that beat expectations am sent the firm’s shares rocketing. There were also strong results for Roche’s immuno-oncology drug Tecentriq in a small population of small cell lung cancer patients, and Takeda’s successful trial of Alunbrig in lung cancer. On the regulatory front, AstraZeneca’s lung cancer drug Imfinzi gained European approval, adding to competition in the sector, while Verastem gained US Food and Drug Administration clearance for its blood cancer drug Copiktra, but with a Black Box warning. 30 September 2018
Pharmaceutical
Following a ‘letter of intent’ back in June, Florida, USA-based Nutriband (OTCQB: NTRB) has now announced the signing of the definitive acquisition agreement to acquire Carmel Biosciences. 27 September 2018
Biotechnology
US biotech Amarin today announced positive top-line results from the Vascepa (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT, a global study of 8,179 statin-treated adults with elevated CV risk. 24 September 2018
Pharmaceutical
Positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT2 inhibitor CVOT conducted to date have been released today. 24 September 2018
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze